Dr. Kenneth S. Hu
Claim this profileNew York University School of Medicine
Studies Head and Neck Cancers
Studies Thyroid Cancer
6 reported clinical trials
16 drugs studied
Area of expertise
1Head And Neck Cancers
2Thyroid Cancer
Stage III
Stage IV
p16 negative
Affiliated Hospitals
Clinical Trials Kenneth S. Hu is currently running
ePVA Monitoring System
for Head and Neck Cancer
The PI and the research team developed the New York University (NYU) Electronic Patient Visit Assessment (ePVA) for head and neck cancer (HNC) as a patient-reported outcome measure (PRO) for the early detection of uncontrolled symptoms. The ePVA is digital patient-reported symptom monitoring system, providing actionable information at point-of-care that enables clinicians to provide real-time interventions. The study aims to advance the science of cancer care delivery by testing the effectiveness of the ePVA as a digital patient-reported monitoring system for patients with HNC in real-world settings and identify implementation strategies that optimize the effectiveness of the ePVA in diverse rural and urban settings. The study hypothesis is that participants assigned to the ePVA arm will have better swallowing, taste and smell, and social function than participants assigned to usual care arm at 4 weeks after completing radiation therapy.
Recruiting1 award N/A3 criteria
Chemotherapy + Radiation Therapy
for Head and Neck Cancer
This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.
Recruiting1 award Phase 2 & 321 criteria
More about Kenneth S. Hu
Clinical Trial Related1 year of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Kenneth S. Hu has experience with
- Cisplatin
- Intensity-Modulated Radiation Therapy
- Photobiomodulation (PBM) Therapy
- Sham PBM
- Cisplatinum
- Dose-Deescalated Treatment
Breakdown of trials Kenneth S. Hu has run
Head and Neck Cancers
Thyroid Cancer
Squamous Cell Carcinoma
Throat Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kenneth S. Hu specialize in?
Kenneth S. Hu focuses on Head and Neck Cancers and Thyroid Cancer. In particular, much of their work with Head and Neck Cancers has involved treating patients, or patients who are undergoing treatment.
Is Kenneth S. Hu currently recruiting for clinical trials?
Yes, Kenneth S. Hu is currently recruiting for 3 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Kenneth S. Hu has studied deeply?
Yes, Kenneth S. Hu has studied treatments such as Cisplatin, Intensity-Modulated Radiation Therapy, Photobiomodulation (PBM) Therapy.
What is the best way to schedule an appointment with Kenneth S. Hu?
Apply for one of the trials that Kenneth S. Hu is conducting.
What is the office address of Kenneth S. Hu?
The office of Kenneth S. Hu is located at: New York University School of Medicine, New York, New York 10016 United States. This is the address for their practice at the New York University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.